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Functional performance and safety 
of bone-anchored prostheses in 
persons with a transfemoral or 
transtibial amputation: a prospective 
one-year follow-up cohort study
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Jan Paul Frölke2, Hendrik van de Meent3, 
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Abstract
Objectives: (1) To compare level of function, activity, health-related quality of life (HRQoL) and 
satisfaction in persons with a lower extremity amputation before surgery and 6- and 12-months after 
implantation of an osseointegration implant and (2) to report adverse events.
Design: Prospective cohort study.
Setting: University medical centre.
Subjects: A total of 40 consecutive persons (median age: 56 years) who received a transfemoral (31) or 
transtibial (9) osseointegration implant, between April 2014 and March 2016.
Intervention: Osseointegration implant surgery followed by a predefined rehabilitation programme.
Main measures: Hip abductor strength, prosthetic use, back pain frequency, postoperative pain, 
mobility level (Timed-Up and Go (TUG) and wheelchair-boundedness), walking ability (6 minute walking 
test (6MWT) and walking distance in daily life), HRQoL, satisfaction regarding the prosthesis, and adverse 
events.
Results: Strength, prosthetic use, walking distance, HRQoL, and satisfaction level increased significantly 
at 6- and 12-month follow-up compared to baseline (P ⩽ 0.002). The TUG showed no change at 
6-month follow-up (P = 0.420) but improved significantly at 12-month follow-up compared to baseline 
(P = 0.005). Wheelchair-boundedness decreased from 12/40 participants at baseline to 0 at follow-ups. 
The 6MWT (P ⩾ 0.038) and back pain (P ⩾ 0.437) did not change over time. Stump pain was present in 
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28/39 and 22/40 of the participants at 6-and 12-month follow-up, respectively. The major adverse events 
were managed successfully and included three dual-cone breakages and four bone fractures. An uneventful 
course was completed by 19/31 transfemoral and 4/9 transtibial bone-anchored prostheses users.
Conclusion: Bone-anchored prostheses lead to improved performance and appear to be safe, so they 
might be considered for persons with socket-related problems.
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Introduction
Socket-suspended prostheses users suffer fre-
quently from socket-related problems. Bone-
anchored prostheses using a transcutaneous 
osseointegration implant might be a solution.1 This 
technique is already used for persons with trauma- 
or tumour-related transfemoral amputation but 
might be also useful for persons with a transtibial 
amputation, and in persons with peripheral vascu-
lar disease.2–4 Especially in these populations, 
insight into the impact of osseointegration implant 
surgery on functional performance and the inci-
dence of adverse events is scarce. Although it is 
hypothesized that bone-anchored prostheses facili-
tate early recovery of mobility level and walking 
ability, insight into the course within the first year 
is missing.
This prospective study focussed on patients with 
a lower extremity amputation who had problems 
with using a socket-suspended prosthesis, and there-
fore, were scheduled for implantation of a press-fit 
osseointegration and a predefined rehabilitation pro-
gramme.4,5 The primary aim was to describe the 
change in the body functions or structures (hereafter 
referred to as level of function), level of activity, 
level of health-related quality of life (HRQoL), and 
level of satisfaction at 6 and 12 months after surgery 
compared to preoperative while using a socket-sus-
pended prosthesis. We hypothesized that hip abduc-
tor strength, prosthetic use, back pain, mobility 
level, walking ability, HRQoL, and prosthetic 
comfort would improve over time.4 Outcomes are 
stratified by amputation level (i.e. transfemoral 
and transtibial), and we analysed the influence of 
wheelchair-boundedness prior osseointegration 
implant surgery on the course of the outcomes. The 
secondary aim of this study was to describe the 
number and severity of adverse events.
Methods
Study design
This is the first report of a prospective cohort study 
with a one-year follow-up. The detailed study pro-
tocol was published previously.4 Following the 
Strengthening the Reporting of Observational stud-
ies in Epidemiology (STROBE) statement, we pre-
sent the results of the time trend analyses with 
follow-ups at 6 and 12 months.
Participants
All consecutive persons who received a transfemo-
ral or transtibial press-fit osseointegration implant 
in our university medical centre (Radboudumc), 
between April 2014 and March 2016, were eligible 
for this study. Persons were eligible for this surgery 
if (1) they were adults with a lower extremity 
amputation suffering from socket-related problems 
contributing to limited prosthetic use,6 and (2) the 
cause of primary amputation was congenital or due 
to a trauma, tumour resection, or stable vascular 
disease. Exclusion criteria for surgery were the 
presence of severe cognitive or psychiatric disor-
ders. Prior to the inclusion, a written informed con-
sent was obtained from all participants. The study 
was conducted according to the principles of the 
Declaration of Helsinki (64th version, 19 October 
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2013). The protocol of this study (registration 
number 2014/196) was approved by the Ethics 
Committees of Radboudumc.
Intervention
Osseointegration implant implantation was per-
formed in two surgeries six to eight weeks apart.2,6 
First, a cementless intramedullary stem was press-fit 
inserted in the femur or tibia (either or not using 
locking screws), and the wound was closed. Second, 
a soft-tissue stoma was created, and a transcutane-
ous adapter (dual-cone with safety weak points) was 
attached into the intramedullary stem (Figure 1). For 
the femur, the osseointegrated prosthetic limb 
(Permedica s.p.a., Via Como, 38, 23807 Merate LC, 
Italy) or integral leg prosthesis (Orthodynamics 
GmbH, Grapengießerstraße Lübeck, Germany 
34, 23556 ) implant was used, for the tibia, a 
patient-specific implant (Orthodynamics GmbH, 
Grapengießerstraße 34, 23556 Lübeck, Germany; 
AQ Implants GmbH, Kurt-Fischer-Straße 22, 22926 
Ahrensburg, Germany) was developed.2 All persons 
started rehabilitation one week after the second sur-
gery, using a full-length prosthesis with the same 
prosthetic components as prior to the osseointegra-
tion implant surgery. Rehabilitation focussed on 
improving hip abductor strength, core stability, sym-
metry of gait parameters, and level of activity.5 The 
duration of the predefined twice weekly rehabilita-
tion programme depended on amputation level and 
ranged from four weeks (transtibial amputation) to 
11 weeks (transfemoral amputation).4 An interlude 
was initiated if pain or limited muscle strength was 
an obstacle to reduce walking aid use. Rehabilitation 
was prolonged if a person was making progress but 
had not yet met the predefined goals.
Study procedures and outcomes
Participants were measured by the treating physio-
therapist preoperatively (baseline) and at the 6- and 
12-month follow-up. The outcomes of this study 
were level of function, activity, HRQoL, and satis-
faction (Table 1). The obtained gait kinematics 
were not reported in this study, in contrast to what 
we described in our study protocol,4 due to insuf-
ficient clinimetric properties of the used measure-
ment systems.7 The adverse events during the study 
period were retrospectively extracted from the par-
ticipants’ medical file using the classification 
described by Al Muderis et al.8 (Supplemental 
Table 1).
Statistical analysis
Categorical descriptive data were presented as 
exact numbers. Percentages were calculated for the 
Figure 1. Radiographs of the used types of osseointegration implants: (a) integral leg prosthesis; (b) 
osseointegrated prosthetic limb; (c) patient-specific implant. Left: intramedullary stem immediately postoperatively 
and right: osseointegrated implant at the 12-month follow-up.
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various levels. For the continuous descriptive data, 
means and standard deviations were calculated for 
normally distributed variables. For data not-nor-
mally distributed median, 25th and 75th percentile 
were used. Demographic and participant character-
istics were used for descriptive statistics.
First, we analysed changes over time in the 
entire cohort. Generalized estimating equations 
with an exchangeable correlation matrix was used 
to analyse binary outcomes (back pain) and nor-
mally distributed continuous outcomes (hip abduc-
tor strength, mobility level: Timed Up and Go 
(TUG) test, walking ability: 6 minute walking test 
(6MWT), HRQoL, and prosthetic comfort). Back 
pain was dichotomized for this analysis into ‘no 
back pain’ and ‘back pain’ (representing the classes 
‘yes, with episodes’ and ‘yes, chronic (daily)’). The 
mean change-over time of the continuous outcomes 
Table 1. Functional outcome measures.
Construct Instrument
Level of function
Hip abductor strength Handheld dynamometer (Nm/kg)4,9
Prosthesis wearing time Questionnaire for persons with a transfemoral amputation Prosthetic use 
Scorea (0–100 points)10
Back pain frequency Single question A5: ‘Did you experience back pain within the previous month?’ 
with three response alternatives; ‘no’, ‘yes, with episodes’ and ‘yes, chronic 
(daily)’
Postoperative stump pain Numeric Rating Scale (0–10 points)11
 Pain location4
Level of activity
Mobility level Medicare Functional Classification Levelb (K0 K4)12
 Special Interest Group in Amputee Medicine Workgroup Amputation 
and Prosthetics mobility scorec (Grade A-F)13
 Use of aids in daily life4
 Timed Up and God (seconds)14
Walking ability 6 minute walking teste (m and m/s)15,16
 Single question B5: ‘How far can you walk in one go in everyday life?’ 
representing a patient-reported estimation of the walking distance in 
daily life in metres
Level of health-related quality of life
Health-related quality of life Questionnaire for persons with a transfemoral amputation Global Scoref 
(0–100 points)10
 Single question C10,17: ‘How would you summarize your overall situation 
as an amputee?’, with five response alternatives; ‘extremely poor’, ‘poor’, 
‘average’, ‘good’ or ‘extremely good’
Level of satisfaction
Prosthetic comfort Prosthetic Comfort Scoreg (0–10 points)5
Global perceived effect of bone-
anchored prosthesis
Single question D4: ‘Would you, with your current knowledge, choose for a 
BAP again?’ with five response alternatives; ‘strongly disagree’, ‘disagree’, 
‘neutral’, ‘agree’ or ‘strongly agree’
aA higher score means longer wearing time.
bKnown as ‘K-levels’ (0–4) in which ‘K0’ represents a non-ambulator and ‘K4’ a high-level prosthesis user.
c‘Grade A’ represents an abandoned prosthesis user and ‘grade F’ a prosthesis user with a normal gait without aids.
dLevel of physical mobility.
eA self-paced test on a 10-m course, representing the submaximal level of functional capacity.
fA higher score means a better health-related quality of life. The global score is not applicable for wheelchair-bound persons with 
the exception of the overall situation item (Question C).
gLevel of satisfaction of the participant in regards to their prosthesis, including the socket or bone-anchored part of the prosthesis.
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and the odds ratio of the dichotomized outcome 
were presented with 99% confidence intervals. A 
99% confidence interval was used to reduce the risk 
of type I errors due to multiple testing. Not-normally 
distributed continuous outcomes (prosthetic use 
and walking ability: walking distance in daily life) 
were visualized with histograms, and change over 
time was tested using the Wilcoxon signed-rank test 
with an alpha level of 0.01. Wheelchair-bound par-
ticipants were completely excluded in the complete 
case time-trend analysis of prosthetic use and walk-
ing ability using the Wilcoxon signed-rank test. In 
the generalized estimating equations analysis, par-
ticipants were only excluded from the follow-up 
moment in which they were wheelchair-bound with 
the exception of the time-trend analysis of hip 
abductor strength which involved all participants.
Second, the change over time of the other cate-
gorical outcomes were analysed using descriptive 
statistics by calculating the change in levels at both 
follow-ups compared to baseline expressed as a 
percentage.
Third, stump pain (intensity and location) and 
global perceived effect of bone-anchored prosthe-
sis were only obtained postoperatively, the course 
of both were analysed using descriptive statistics.
Moreover, outcomes are presented for sub-
groups stratified by amputation level using descrip-
tive statistics. Within the subgroups, we also 
present the results stratified by the presence of 
wheelchair-boundedness before surgery.
All analyses were performed using SPSS ver-
sion 23 (SPSS Inc, Chicago, Illinois, USA).
Results
All 40 eligible participants were included in the 
study; 31 participants received a transfemoral osse-
ointegration implant and nine a transtibial osseoin-
tegration implant (Table 2 and Figure 2). The 
median time from primary amputation was 
eight years (range: 1–46 years). A total of 12 partici-
pants were wheelchair-bound at baseline (Figure 3). 
The median rehabilitation duration was 24 weeks 
(range: 6–62 weeks, 7–71 sessions) and nine weeks 
(range: 3–22 weeks, 7–21 sessions) for participants 
with a transfemoral and transtibial bone-anchored 
prosthesis, respectively. No participants were lost to 
follow-up. The 6- and 12-month follow-up meas-
urements were completed by 39 and 40 participants, 
respectively (Table 3 and Figure 3). In the follow-
ing paragraphs, we will first detail the impact of the 
intervention at the 12-month follow-up; second, we 
present the six-month follow-up results to increase 
the insight into the course within the first year; 
third, we describe the results for the stratified 
cohorts; and finally, the adverse events within the 
study period will be detailed.
Functional outcomes: 12-month follow-up
At level of function, hip abductor strength increased 
significantly (P ⩽ 0.002) at 12-month follow-up 
(residual limb: β = 0.16, standard error = 0.03 
(23%), sound limb: β = 0.17, standard error = 
0.03 (20%) compared to baseline. Prosthesis wear-
ing time increased significantly (P < 0.001) at 
12-month follow-up compared to baseline 
(Appendix A). Back pain did not change statisti-
cally significant over time (P = 0.437). Stump pain 
was present in 22/40 (55%) of the participants at 
12-month follow-up. Of these participants, 14/22 
(64%) experienced on average a mild stump pain 
on the distal part of the stump (circular or the soft-
tissue stoma) at 12-month follow-up.
At the level of activity patient-reported mobility 
level increased at 12-month follow-up relative to 
baseline represented by an increased percentage of 
participants classified as Medicare Functional 
Classification Level K3–4 and Special Interest 
Group in Amputee Medicine Workgroup 
Amputation and Prosthetics mobility score grade 
E–F at 12-month follow-up (K3–4: 11/40 (28%), 
grade E–F: 11/40 (28%). None of the participants 
were wheelchair-bound at 12-month follow-up. 
The percentage of unaided walkers increased at 
12-month follow-up (indoors: 12/40 (30%), out-
doors: 9/40 (23%) compared to baseline. The phys-
ical performance measurement (i.e. TUG) increased 
significantly (P = 0.005) by β = –1.9, standard 
error = 0.7 (17%) at 12-month follow-up com-
pared to baseline. Walking ability represented by 
the 6MWT increased, although non-significant 
(P = 0.038), by β = 25, standard error = 12 (8%) 
at 12-month follow-up compared to baseline. 
Patient-reported walking distance in daily life 
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Table 2. Demographic, participant, and rehabilitation characteristics.
Entire cohort Transfemoral cohort Transtibial cohort
Participants, n 40 31 9
Sex (male), n (%) 22 (55) 17 (55) 5 (56)
Age at inclusion (years), median (25th PCTL; 75th 
PCTL)
55.5 (43.3; 59.0) 56.0 (45.0; 59.0) 43.0 (29.5; 57.5)
Time from primary amputation to inclusion (years), 
median (25th PCTL; 75th PCTL)
8.0 (3.0; 19.8) 6.0 (3.0; 26.0) 11.0 (3.0; 17.5)
BMI (kg/m2), mean (SD) 29.0 (5.7) 29.0 (5.7) 28.9 (5.8)
Amputation  
 Unilateral, n (%) 38 (95) 19 (94) 9 (100)
 Bilateral, n (%) 2 (5) 2 (7) 0 (0)
Cause of primary amputation  
 Trauma, n (%) 22 (55) 17 (55) 5 (56)
 Tumour, n (%) 7 (18) 7 (23) 0 (0)
 Vascular, n (%) 5 (13) 3 (10) 2 (22)
 Other, n (%) 6 (15) 4 (13) 2 (22)
Wheelchair-bound at baseline, n (%) 12 (30) 10 (32) 2 (22)
Primary amputation levela  
 Transfemoral amputation, n (%) 31 (74) 30 (97)  
 Knee disarticulation, n (%) 1 (2) 1 (3)  
 Transtibial amputation, n (%) 9 (21) 9 (90)
 Foot amputation, n (%) 1 (2) 1 (10)
Stump characteristics (cm)  
 Proximal circumference, mean (SD) 57.0 (7.2) 55.7 (6.1) 61.7 (9.1)
 Length  
  Transfemoral amputation, mean (SD) 22.1 (4.7) 22.1 (4.7)  
  Knee disarticulation, mean (SD) 40.5 40.5  
  Transtibial amputation, mean (SD) 51.8 (4.8) 51.8 (4.8)
  Foot amputation 74.0 74.0
Extremities treated, nb 41 32 9
  Integral leg prosthesis (chromium-cobalt-
molybdenum), n (%)
17 (41) 17 (53)  
 Osseointegrated prosthetic limb (titanium), n (%) 15 (37) 15 (47)  
  Patient-specific implant (chromium-cobalt-
molybdenum), n (%)
1 (2) 1 (11)
 Patient-specific implant (titanium), n (%)c 8 (20) 8 (89)
Rehabilitation duration (weeks), median (25th PCTL; 
75th PCTL)
19.7 (10.1; 25.9) 23.7 (14.0; 28.0) 9.0 (5.4; 16.3)
Rehabilitation sessions (n), median  
(25th PCTL; 75th PCTL)
20.0 (12.3; 30.0) 26.0 (15.0; 31.0) 10.0 (8.5; 17.0)
BMI: body mass index accounting for the limb loss using the adjusted body weight; PCTL: percentile; SD: standard deviation.
aTotal extremities = 42: one participant had a bilateral transfemoral amputation, and one participant had a bilateral amputation of 
which right on transfemoral level and left on transtibial level.
bThe participant with bilateral transfemoral amputation was treated with a titanium implant on two limbs, the other bilateral 
participant was treated with a titanium implant on the transfemoral residual limb.
cTwo participants received the osseointegration implant and dual-cone in a single-stage surgical procedure because closure of the 
wound after inserting the osseointegration implant was not possible due to marginal coverage of the tibia with soft tissue.
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increased significantly (P ⩽ 0.001) at 12-month 
follow-up compared to baseline (Appendix A).
HRQoL increased significantly (P < 0.001) by 
β = 25, standard error = 4 (54%) at 12-month 
Figure 2. Bone-anchored prostheses. Left: transfemoral bone-anchored prosthesis and right: transtibial bone-
anchored prosthesis.
Figure 3. Flow chart illustrating the number of participants within the study.
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follow-up compared to baseline. The overall situa-
tion as an amputee improved at 12-month follow-
up, illustrated by the increased proportion (6/40 
(15%) of the participants that scored good or 
extremely good on question C at follow-up com-
pared to baseline.
At the level of satisfaction prosthetic comfort 
increased significantly (P < 0.001) by β = 3.2, 
standard error = 0.5 (65%) at 12-month follow-up 
compared to baseline. Of all participants, 39/40 
(98%) would again opt for the bone-anchored pros-
thesis at 6- and 12-month follow-up, respectively.
Functional outcomes: six-month follow-up
At six-month follow-up, all the above presented 
outcomes measures improved significantly as well 
compared to baseline with the exception of the 
TUG test (P = 0.420) and the 6MWT (P = 0.429). 
The outcome measures which were only analysed 
with descriptive statistics revealed at six-month 
follow-up similar trends as at 12-months follow-up 
compared to baseline. The number of participants 
experiencing stump pain was higher at six-month 
follow up (28/39 (72%) compared to the 12-month 
follow-up (22/40 (55%). At six-month follow-up 
37/39 (95%), participants would again opt for the 
bone-anchored prosthesis.
Functional outcomes: stratified cohorts
Stratification based on amputation level revealed 
the following insights. In the transtibial bone-
anchored prosthesis users, we observed higher 
baseline values compared to transfemoral bone-
anchored prosthesis users, with the exception of 
walking distance in daily life and prosthetic com-
fort (Supplemental Tables 2 and 3). The increase 
over time, in percentages, was larger in transtibial 
bone-anchored prosthesis users compared to trans-
femoral bone-anchored prosthesis users, with the 
exception of hip abductor strength and prosthesis 
wearing time. At the 12-month follow-up less tran-
stibial bone-anchored prosthesis users experienced 
stump pain than transfemoral bone-anchored pros-
thesis users (transfemoral: 20/31 (65%), transtibial: 
2/9 (22%), and the intensity of the pain was the 
lowest in transtibial bone-anchored prosthesis users 
(transfemoral: 3.8 points and transtibial: 1.2 points).
Stratification on both amputation level and 
wheelchair-boundedness revealed that in transfem-
oral bone-anchored prosthesis users (Supplemental 
Table 2), all outcomes of the non-wheelchair-
bound participants were superior compared to 
wheelchair-bound participants, with the exception 
of HRQoL at 12-month follow-up and prosthesis 
comfort at six-month follow-up. Contrary to the 
entire cohort, the residual limb hip abductor 
strength decreased by 10% at six-month follow-up 
(0.57 Nm/kg, SD = 0.19) and showed no change at 
12-month follow-up (0.63 Nm/kg, SD = 0.23) 
compared to baseline (0.63 Nm/kg, SD = 0.21) in 
the wheelchair-bound subgroup. In both transfem-
oral and transtibial bone-anchored prosthesis users, 
there was a trend that non-wheelchair-bound par-
ticipants had less back pain at the follow-ups com-
pared to baseline, while back pain frequency 
increased over time in wheelchair-bound partici-
pants (Supplemental Table 4).
Adverse events
The major adverse events that occurred are as fol-
lows: (1) three breakages of the dual-cone, all suc-
cessfully replaced and (2) four bone fractures 
(caused by a fall accident in daily use), all success-
fully treated. No breakage of the intramedullary 
stem, bone infection, or (a)septic implant loosen-
ing occurred. Minor adverse events concerned in 
particular low-grade soft-tissue infections; 8/18 
(44%) of the participants with a chromium-cobalt-
molybdenum osseointegration implant and 5/22 
(23%) participants with a titanium osseointegration 
implant had one of more low-grade soft-tissue 
infections. In total, 19/31 (61%) and 4/9 (44%) of 
the participants with a transfemoral bone-anchored 
prosthesis and transtibial bone-anchored prosthe-
sis, respectively, had an uneventful course 
(Supplemental Table 5).
Discussion
Outcomes on the level of function, activity, HRQoL, 
and satisfaction improved significantly after 
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12-months use of a bone-anchored prosthesis com-
pared to the use of a socket-suspended prosthesis 
with the exception of the 6MWT. Six-months after 
surgery, this improvement was already visible in 
majority of the outcomes, including a complete 
absence of wheelchair-boundedness. All our a pri-
ori hypotheses were correct with the exception of 
the expected decrease of back pain frequency which 
was only found in the subgroup of participants who 
were non-wheelchair-bound at baseline.
Stratification based on amputation level showed 
that stump pain was in particular a persistent prob-
lem in participants with a transfemoral bone-
anchored prosthesis and seemed to be related to the 
soft-tissue stoma. A possible explanation for this 
finding could be that transfemoral bone-anchored 
prosthesis users experience more mechanical fric-
tion between the soft tissue and the dual-cone due 
to more excessive soft tissue in the stump than 
transtibial bone-anchored prosthesis users.2 At 
least, 95% of the participants would again opt for a 
bone-anchored prosthesis, demonstrating that the 
functional improvements and the absence of 
socket-related problems outweighs the presence of 
stump pain and adverse events.
Stratification based on wheelchair-boundedness 
revealed that wheelchair-boundedness negatively 
influenced the ability of transfemoral bone-
anchored prosthesis users to recover and generally 
influence the presence of back pain.
The incidence of implant-related major adverse 
events was 8%. An uneventful course was more 
common in transfemoral bone-anchored prosthesis 
user than in transtibial bone-anchored prosthesis 
users.
The previously reported improvement in pros-
thesis wearing time6,18 and HRQoL6,18,19 are compa-
rable to our findings. In the 12-month and 22-month 
follow-up study by Van de Meent et al.6 and Muderis 
et al.,19 respectively, participants with a transfemo-
ral bone-anchored prosthesis improved on the TUG 
test (32%–49%) and the 6MWT (40%–46%) com-
pared to baseline. Our transfemoral cohort per-
formed only 14% and 4% better on the TUG and 
6MWT, respectively, despite comparable baseline 
values and participant characteristics. This discrep-
ancy in results might be explained by the difference 
in the length of the 6-minute walking course 
between the studies and the decreased walking aid 
use over time found in our study.20,21 We used a 
10-m 6MWT course, while Van de Meent et al.6 and 
Muderis et al.19 used a 20-m and 12.5-m 6MWT 
course, respectively (obtained by contacting the 
authors). Both authors did not report the used walk-
ing aids during the tests. It is easier to improve on a 
long 6MWT course than on a short 6MWT 
course.20,21 In our study, walking aid use decreased 
over time. Although, this is beneficial for daily life 
activities, it does not implicate that unaided walking 
improves walking speed.
Similar to our finding, Hagberg et al.22 found no 
change in back pain after transfemoral osseointegra-
tion implant surgery. However, wheelchair-bound-
edness stratification revealed that back pain 
frequency of non-wheelchair-bound participants 
decreased over time compared to baseline while 
wheelchair-bound participants showed an opposite 
trend. This trend in change of back pain is possibly 
associated with the change in hip abductor strength 
as observed in the transfemoral bone-anchored pros-
thesis users. The level of satisfaction was high in our 
cohort which is similar as found in another cohort of 
transfemoral bone-anchored prosthesis users.23
To our knowledge, this study is the first to report 
(1) functional outcomes and adverse events of a 
consecutive cohort of transtibial bone-anchored 
prosthesis users, (2) a six-month follow-up, (3) hip 
abductor strength outcomes, (4) the prevalence and 
intensity of postoperative stump pain, and (5) the 
real rehabilitation duration and intensity of a cohort 
of bone-anchored prosthesis users using a press-fit 
osseointegration implant. In literature, various 
rehabilitation programmes are described, ranging 
from 4 to 14 weeks5,6,19,24 for persons with a press-
fit osseointegration implant and six months for per-
sons with a screw-type osseointegration implant.17 
This cohort study showed that there are differences 
in the predefined duration of the rehabilitation pro-
grammes and daily clinical practice, while the 
number of rehabilitation sessions is comparable. In 
our study, 19/31 (61%) of the transfemoral and 4/9 
(44%) of the transtibial bone-anchored prosthesis 
users needed an interlude in their rehabilitation 
programme due to pain or limited muscle strength 
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which can explain the observed difference in reha-
bilitation duration. A recently published study of 
persons with a screw-type osseointegration implant 
revealed also a variability in rehabilitation duration 
despite a predefined rehabilitation programme.25
This study contains some limitations. First, the 
adverse events were extracted from the participants’ 
Radboudumc medical file. Minor adverse events 
(e.g. infection grade 1A and 2A) typically treated by 
participants’ general practitioners could have been 
missed resulting in an underestimation of these 
minor adverse events. Second, the sample size of 
the presented subgroups was small due to stratifica-
tion on two levels, consequently only descriptive 
statistics were used to analyse the time trend of 
these strata. In future reports of this ongoing study,4 
we will present larger samples of each stratum 
thereby increasing the generalisability of the strati-
fied results. Third, the outcome measures were col-
lected by the treating physiotherapist as part of 
usual care. A blinded assessor is preferable to 
decrease the risk of measurement bias. This was not 
an eligible option in this study because blinding for 
the type of prosthesis is not possible. Fourth, self-
reported outcomes could have been biased by 
response shift resulting in an overestimation of the 
benefits of bone-anchored prostheses compared to 
socket-suspended prostheses.26 We measured 
mobility level and walking ability both with patient-
reported outcome measures as with performance 
tests, which is important because they measure dif-
ferent aspects of the construct and may vary in 
responsiveness.27,28 The findings at six-month fol-
low-up and in part at 12-month follow-up were 
inconclusive because the patient-reported outcomes 
improved while the performance tests did not 
change significantly compared to baseline. In future 
research, the use of an activity tracker can be of 
added value to gain insight into this discrepancy.27 
Fifth, we used a robust measure to investigate back 
pain. Because of this, insight into back pain inten-
sity and influence of back pain on the level of func-
tional difficulties is still missing. Future research 
should include more sensitive measures such as an 
NRS11 and the Revised Oswestry Low Back Pain 
Disability Questionnaire,29,30 and should explore 
possible underlying mechanisms by measuring gait 
kinematic parameters. Finally, because this is an 
observational study, we are not able to determine 
the relative effectiveness of the bone-anchored 
prosthesis compared to the socket-suspended pros-
thesis. Controlled clinical studies are necessary 
although this provides an ethical challenge, while 
currently osseointegration implant surgery is not 
used as a primary intervention after amputation but 
as a last resort for persons suffering from socket-
related problems.
Besides insight into health benefits, it is impor-
tant to gain insight into the cost-effectiveness before 
implementation on a larger scale is initiated. A 
recent cost-effectiveness analysis31 showed that 
bone-anchored prostheses had an incremental cost 
per quality-adjusted life-year gained of €83,374 
compared with socket-suspended prostheses. 
However, a decline in utility values for persons with 
a socket-suspended prosthesis, which is common in 
the target population for a bone-anchored prosthe-
sis, resulted in a substantial reduction of the cost per 
quality-adjusted life-year up to €18,952 per quality-
adjusted life-year. These results are gathered in per-
sons using a screw-type osseointegration implant, 
which has a different treatment procedure compared 
to the press-fit osseointegration implants. Cost-
effectiveness should be included in future research 
in persons using a press-fit osseointegration implant 
to gain insight into the impact of the type of implant, 
the treatment regimens, and the country in which 
the care is given on the cost-effectiveness of bone-
anchored prosthesis.
Clinical messages
•• Ratio between functional benefits of 
bone-anchored prosthesis and adverse 
events appears sufficient, and therefore, 
an eligible alternative for socket-sus-
pended prostheses in persons with 
socket-related problems.
•• Wheelchair-boundedness decreased to 
zero, walking distance increased.
•• Around 98% of the participants would 
again opt for the bone-anchored prosthesis.
•• Adverse events occurred frequently but 
could be managed with relatively simple 
measures.
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